Structure-Based Discovery and Optimization of Furo[3,2- c ]pyridin-4(5 H )-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors
Junhua Li,Cheng Zhang,Hongrui Xu,Chao Wang,Ruibo Dong,Hui Shen,Xiaoxi Zhuang,Xiaoshan Chen,Qiu Li,Jibu Lu,Maofeng Zhang,Xishan Wu,Kerry M. Loomes,Yulai Zhou,Yan Zhang,Jinsong Liu,Yong Xu
DOI: https://doi.org/10.1021/acs.jmedchem.2c00100
IF: 8.039
2022-03-25
Journal of Medicinal Chemistry
Abstract:Pan-bromodomain and extra terminal (Pan-BET) inhibitors show profound efficacy but exhibit pharmacology-driven toxicities in clinical trials. The development of domain-selective BET inhibitors to separate efficacy and toxicity is urgently needed. Herein, we report a series of furo[3,2-c]pyridin-4(5H)-one derivatives as novel BD2-selective BET inhibitors. The representative compound 8l (XY153) potently bound to BRD4 BD2 with an half-maximum inhibitory concentration (IC50) value of 0.79 nM and displayed 354-fold selectivity over BRD4 BD1. Besides, 8l exhibited 6-fold BRD4 BD2 domain selectivity over other BET BD2 domains. Compound 8l displayed potent antiproliferative activity against multiple tumor cell lines, especially MV4-11 (IC50 = 0.55 nM), while showing weak cytotoxicity against the normal lung fibroblast cell line. It highlights the safety profile of this series of BD2 inhibitors. 8l also demonstrated good metabolic stability in vitro. These data indicate that 8l may serve as a new and valuable lead compound for the development of potential therapeutics against acute myeloid leukemia (AML).The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00100.Statistics of the data set and structure refinement of 7o, 7u, 8a, 8f, 8k, and 8l (Table S1); Kon, Koff, and Kd values of 8l, 8m, and 3 in the BLI assay (Table S2); inhibition rates of 8j–m, and 3 by alphascreen (Table S3); IC50 values of 8l and 3 in different cell lines (Table S4); structure overlap of 8k with 4 in BRD2 BD2 (Figure S1); dose–response curves of 8l, 8m, and 3 in the BLI assay (Figure S2); binding affinity of compounds 7b, 7r, 7y, 8j, 8k, 8l, 8m, and 1 in the TSA assay (Figure S3); melting curves of 8l, 8m, and 1 in the TSA assay (Figure S4); inhibitory curve of compounds 8l and 3 in different cell lines (Figure S5); 1H NMR and 13C NMR for all final compounds; and HPLC traces for 8h–m (PDF)Molecular formula strings for compounds with associated biological data (CSV)Homology models for the core structure with BRD2 BD2 (PDB)Crystal (X-ray) structure validation reports for compound 7o (PDF)Crystal (X-ray) structure validation reports for compound 7u (PDF)Crystal (X-ray) structure validation reports for compound 8a (PDF)Crystal (X-ray) structure validation reports for compound 8f (PDF)Crystal (X-ray) structure validation reports for compound 8k (PDB: 7WMQ) (PDF)Crystal (X-ray) structure validation reports for compound 8l (PDB: 7WLN) (PDF)Crystal (X-ray) structure validation reports for compound 8k (PDB: 7WJS) (PDF)Crystal (X-ray) structure validation reports for compound 8l (PDB: 7WKY) (PDF)This article has not yet been cited by other publications.
chemistry, medicinal